It is NBE-Therapeutics’ vision to become an internationally recognized leader and pioneer for the development of innovative and effective antibody-based medicines. The main focus will be on the development of next-generation Antibody Drug Conjugate (ADCs) products for the treatment of cancer.
In order to achieve this, NBE Therapeutics has developed potent antibody discovery and enzymatic, site-specific toxin-antibody conjugation technologies and plans to utilize these pioneering technologies for the development of a robust therapeutic antibody and ADC drug pipeline.
Value adding collaborations and product licensing will be pursued throughout every stage of company development.
- Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
- London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.
- Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference